Kalpit Patel
Stock Analyst at B. Riley Securities
(1.14)
# 3,561
Out of 4,855 analysts
55
Total ratings
31.71%
Success rate
-10.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $47.62 | +26.00% | 3 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.55 | +63.74% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $23.56 | +57.05% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $21.49 | +11.68% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.60 | +118.75% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $6.42 | +40.19% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.46 | +124.22% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.69 | +314.20% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $9.23 | +333.37% | 2 | Sep 20, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.32 | +841.62% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $14.68 | +36.24% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.30 | +597.67% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $7.51 | -20.05% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $11.45 | +214.41% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $4.17 | -28.06% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.42 | +1,167.61% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.07 | +141.55% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.39 | +1,253.18% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $11.32 | +562.54% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $47.62
Upside: +26.00%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.55
Upside: +63.74%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $23.56
Upside: +57.05%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $21.49
Upside: +11.68%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.60
Upside: +118.75%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $6.42
Upside: +40.19%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.46
Upside: +124.22%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.69
Upside: +314.20%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.23
Upside: +333.37%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.32
Upside: +841.62%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $14.68
Upside: +36.24%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.30
Upside: +597.67%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $7.51
Upside: -20.05%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $11.45
Upside: +214.41%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $4.17
Upside: -28.06%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.42
Upside: +1,167.61%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.07
Upside: +141.55%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.39
Upside: +1,253.18%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $11.32
Upside: +562.54%